A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT ID: NCT00055523
Last Updated: 2006-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
300 participants
INTERVENTIONAL
2002-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adalimumab (D2E7)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CDAI score at baseline of between 220 and 450
* Normal laboratory parameters
* Willing and able to give informed consent
Exclusion:
* Diagnosis of ulcerative colitis
* Women cannot be pregnant or breastfeeding
* No previous use of infliximab or other anti-TNF antagonists
* No previous history of tuberculosis or listeria infection
* No previous history of cancer other than successfully treated skin cancer
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen B Hanauer, MD
Role: PRINCIPAL_INVESTIGATOR
University of Chicago Department of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gastroenterology Associates of the East Bay
Berkeley, California, United States
Long Beach Gastroenterology Assoc.
Long Beach, California, United States
Sharp Rees-Stealy Medical Group
San Diego, California, United States
Gastroenterology Assoc. of Fairfield Co.
Bridgeport, Connecticut, United States
Cleveland Clinic Florida
Weston, Florida, United States
Shafran Gastroenterology Center
Winter Park, Florida, United States
Atlanta Gastroenterology Assoc.
Atlanta, Georgia, United States
Southeastern Digestive & Liver Disease
Savannah, Georgia, United States
Northwest Gastroenterologists, S.C.
Arlington Heights, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Drug Research Services, Inc.
Metairie, Louisiana, United States
LSU School of Medicine
New Orleans, Louisiana, United States
Digestive Disorders Associates
Annapolis, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States
Mayo Clinic and Mayo Foundation
Rochester, Minnesota, United States
Gastroenterology and Hepatology
Kansas City, Missouri, United States
Glenn Gordon, MD
Mexico, Missouri, United States
Deaconess Billings Clinic Research Division
Billings, Montana, United States
Gastroenterology Specialties, P.C.
Lincoln, Nebraska, United States
Long Island Clinical Research Associates
Great Neck, New York, United States
NY Center for Clinical Research
Lake Success, New York, United States
New York Presbyterian Hospital
New York, New York, United States
Daniel Present
New York, New York, United States
Rochester Institute for Digestive Diseases
Rochester, New York, United States
UNC School of Medicine
Chapel Hill, North Carolina, United States
Charlotte Gastroenterology and Hepatology
Charlotte, North Carolina, United States
Carolina Research Associates
Charlotte, North Carolina, United States
Wake Research Associates
Raleigh, North Carolina, United States
Digestive Health Specialists
Winston-Salem, North Carolina, United States
Consultants for Clinical Research
Cincinnati, Ohio, United States
Oklahoma Foundation for Digestive Disease
Oklahoma City, Oklahoma, United States
Research Solutions
Tulsa, Oklahoma, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Peter Molloy, MD
Pittsburgh, Pennsylvania, United States
Diseases of the Digestive System
Chattanooga, Tennessee, United States
Nashville Medical Research Institute
Nashville, Tennessee, United States
Charlottesville Medical Research
Charlottesville, Virginia, United States
Northwest Gastroenterology
Bellevue, Washington, United States
Inland Empire Gastroenterology
Spokane, Washington, United States
Tacoma Digestive Disease Center
Tacoma, Washington, United States
Wisconsin Center for Advanced Research
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OO, Ainsworth MA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012 Dec;18(12):2209-17. doi: 10.1002/ibd.22910. Epub 2012 Feb 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M02-403
Identifier Type: -
Identifier Source: org_study_id